Generating iPSCs: translating cell reprogramming science into scalable and robust biomanufacturing strategies

Marli Silva; Laurence Daheron; Hannah Hurley; Kim Bure; Richard Barker; Andrew J Carr; David Williams; Hae-Won Kim; Anna French; Pete J Coffey; Justin J Cooper-White; Brock Reeve; Mahendra Rao; Evan Y Snyder; Kelvin S Ng; Benjamin E Mead; James A Smith; Jeffrey M Karp; David A Brindley; Ivan Wall

doi:10.1016/j.stem.2014.12.013

Generating iPSCs: translating cell reprogramming science into scalable and robust biomanufacturing strategies

Marli Silva
, Laurence Daheron
, Hannah Hurley
, Kim Bure
, Richard Barker
, Andrew J Carr
, David Williams
, Hae-Won Kim
, Anna French
, Pete J Coffey
, Justin J Cooper-White
, Brock Reeve
, Mahendra Rao
, Evan Y Snyder
, Kelvin S Ng
, Benjamin E Mead
, James A Smith
, Jeffrey M Karp
, David A Brindley
, Ivan Wall

The Advanced Centre for Biochemical Engineering, Department of Biochemical Engineering, University College London, Gordon St, London, WC1H 0AH, UK.
Harvard Stem Cell Institute, Cambridge, MA 02138, USA.
The Oxford-UCL Centre for the Advancement of Sustainable Medical Innovation, University of Oxford, Oxford, OX3 9DU, UK.
TAP Biosystems, Royston, Hertfordshire, SG8 5WY, UK.
The Oxford-UCL Centre for the Advancement of Sustainable Medical Innovation, University of Oxford, Oxford, OX3 9DU, UK; Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Nuffield Orthopaedic Centre, University of Oxford, Oxford, OX3 7LD, UK.
Centre for Biological Engineering, Wolfson School of Mechanical and Manufacturing Engineering; Loughborough University; Loughborough LE11 3TU United Kingdom
Department of Nanobiomedical Science and BK21 Plus NBM Global Research Center of Regenerative Medicine, Dankook University, Cheonan 330-714, Republic of Korea; Institute of Tissue Regeneration Engineering, Dankook University Graduate School, Cheonan 330-714, Republic of Korea; Department of Dental Biomaterials, School of Dentistry, Dankook University, Shinbu-dong, Cheonan 330-714, Republic of Korea.
Ocular Biology and Therapeutics, Institute of Ophthalmology, University College London, London, EC1V 9EL, UK; Neuroscience Research Institute, University of California, Santa Barbara, CA 93106-5060, USA.
Australian Institute for Bioengineering & Nanotechnology, The University of Queensland, St. Lucia, QLD 4072, Australia; School of Chemical Engineering, The University of Queensland, St. Lucia, QLD 4072, Australia; Materials Science and Engineering Division, CSIRO, Clayton, VIC 3169, Australia.
New York Stem Cell Foundation, New York, NY 10023, USA.
Burnham Medical Research Institute, La Jolla, CA 92037, USA; Department of Pediatrics, University of California, San Diego, La Jolla, CA 92161, USA; Sanford Consortium for Regenerative Medicine, La Jolla, CA 92037, USA.
Harvard Stem Cell Institute, Cambridge, MA 02138, USA; Division of Biomedical Engineering, Department of Medicine, Center for Regenerative Therapeutics, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA; Harvard-MIT Division of Health Sciences and Technology, Cambridge, MA 02139, USA.
Harvard Stem Cell Institute, Cambridge, MA 02138, USA; The Oxford-UCL Centre for the Advancement of Sustainable Medical Innovation, University of Oxford, Oxford, OX3 9DU, UK.
Harvard Stem Cell Institute, Cambridge, MA 02138, USA; The Oxford-UCL Centre for the Advancement of Sustainable Medical Innovation, University of Oxford, Oxford, OX3 9DU, UK; Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Nuffield Orthopaedic Centre, University of Oxford, Oxford, OX3 7LD, UK; Centre for Behavioural Medicine, UCL School of Pharmacy, University College London, London WC1H 9JP, UK.

Research output: Contribution to journal › Article › peer-review

58 Citations (Scopus)

Abstract

Induced pluripotent stem cells (iPSCs) have the potential to transform drug discovery and healthcare in the 21(st) century. However, successful commercialization will require standardized manufacturing platforms. Here we highlight the need to define standardized practices for iPSC generation and processing and discuss current challenges to the robust manufacture of iPSC products.

Original language	English
Pages (from-to)	13-17
Number of pages	5
Journal	Cell stem cell
Volume	16
Issue number	1
DOIs	https://doi.org/10.1016/j.stem.2014.12.013
Publication status	Published - 8 Jan 2015

Bibliographical note

Keywords

Animals
Cell Culture Techniques/methods
Cellular Reprogramming
Humans
Induced Pluripotent Stem Cells/cytology
Reproducibility of Results
Stem Cell Transplantation

Access to Document

10.1016/j.stem.2014.12.013

Cite this

Silva, M., Daheron, L., Hurley, H., Bure, K., Barker, R., Carr, A. J., Williams, D., Kim, H.-W., French, A., Coffey, P. J., Cooper-White, J. J., Reeve, B., Rao, M., Snyder, E. Y., Ng, K. S., Mead, B. E., Smith, J. A., Karp, J. M., Brindley, D. A., & Wall, I. (2015). Generating iPSCs: translating cell reprogramming science into scalable and robust biomanufacturing strategies. Cell stem cell, 16(1), 13-17. https://doi.org/10.1016/j.stem.2014.12.013

@article{c0cf972498d54d45b57729671ec29e3c,

title = "Generating iPSCs: translating cell reprogramming science into scalable and robust biomanufacturing strategies",

abstract = "Induced pluripotent stem cells (iPSCs) have the potential to transform drug discovery and healthcare in the 21(st) century. However, successful commercialization will require standardized manufacturing platforms. Here we highlight the need to define standardized practices for iPSC generation and processing and discuss current challenges to the robust manufacture of iPSC products. ",

keywords = "Animals, Cell Culture Techniques/methods, Cellular Reprogramming, Humans, Induced Pluripotent Stem Cells/cytology, Reproducibility of Results, Stem Cell Transplantation",

author = "Marli Silva and Laurence Daheron and Hannah Hurley and Kim Bure and Richard Barker and Carr, \{Andrew J\} and David Williams and Hae-Won Kim and Anna French and Coffey, \{Pete J\} and Cooper-White, \{Justin J\} and Brock Reeve and Mahendra Rao and Snyder, \{Evan Y\} and Ng, \{Kelvin S\} and Mead, \{Benjamin E\} and Smith, \{James A\} and Karp, \{Jeffrey M\} and Brindley, \{David A\} and Ivan Wall",

year = "2015",

month = jan,

day = "8",

doi = "10.1016/j.stem.2014.12.013",

language = "English",

volume = "16",

pages = "13--17",

journal = "Cell stem cell",

issn = "1875-9777",

publisher = "Cell Press",

number = "1",

}

Silva, M, Daheron, L, Hurley, H, Bure, K, Barker, R, Carr, AJ, Williams, D, Kim, H-W, French, A, Coffey, PJ, Cooper-White, JJ, Reeve, B, Rao, M, Snyder, EY, Ng, KS, Mead, BE, Smith, JA, Karp, JM, Brindley, DA & Wall, I 2015, 'Generating iPSCs: translating cell reprogramming science into scalable and robust biomanufacturing strategies', Cell stem cell, vol. 16, no. 1, pp. 13-17. https://doi.org/10.1016/j.stem.2014.12.013

TY - JOUR

T1 - Generating iPSCs

T2 - translating cell reprogramming science into scalable and robust biomanufacturing strategies

AU - Silva, Marli

AU - Daheron, Laurence

AU - Hurley, Hannah

AU - Bure, Kim

AU - Barker, Richard

AU - Carr, Andrew J

AU - Williams, David

AU - Kim, Hae-Won

AU - French, Anna

AU - Coffey, Pete J

AU - Cooper-White, Justin J

AU - Reeve, Brock

AU - Rao, Mahendra

AU - Snyder, Evan Y

AU - Ng, Kelvin S

AU - Mead, Benjamin E

AU - Smith, James A

AU - Karp, Jeffrey M

AU - Brindley, David A

AU - Wall, Ivan

PY - 2015/1/8

Y1 - 2015/1/8

N2 - Induced pluripotent stem cells (iPSCs) have the potential to transform drug discovery and healthcare in the 21(st) century. However, successful commercialization will require standardized manufacturing platforms. Here we highlight the need to define standardized practices for iPSC generation and processing and discuss current challenges to the robust manufacture of iPSC products.

AB - Induced pluripotent stem cells (iPSCs) have the potential to transform drug discovery and healthcare in the 21(st) century. However, successful commercialization will require standardized manufacturing platforms. Here we highlight the need to define standardized practices for iPSC generation and processing and discuss current challenges to the robust manufacture of iPSC products.

KW - Animals

KW - Cell Culture Techniques/methods

KW - Cellular Reprogramming

KW - Humans

KW - Induced Pluripotent Stem Cells/cytology

KW - Reproducibility of Results

KW - Stem Cell Transplantation

UR - https://www.sciencedirect.com/science/article/pii/S1934590914005712?via%3Dihub

U2 - 10.1016/j.stem.2014.12.013

DO - 10.1016/j.stem.2014.12.013

M3 - Article

C2 - 25575079

SN - 1875-9777

VL - 16

SP - 13

EP - 17

JO - Cell stem cell

JF - Cell stem cell

IS - 1

ER -

Generating iPSCs: translating cell reprogramming science into scalable and robust biomanufacturing strategies

Abstract

Bibliographical note

Keywords

Access to Document

Other files and links

Fingerprint

Cite this